European Physician and Payer Perspective on Current Mainstays and Novel Entrants in the Age of Austerity
Parkinson’s disease (PD) is a debilitating chronic neurodegenerative disease affecting more than one million people in the five major European pharmaceutical markets (France, Germany, Italy, Spain, United Kingdom; EU5). At the core of PD treatment is long-generic standard of care levodopa (multiple brands, generics), but drugs from several other classes, including dopamine agonists and MAO-B inhibitors, have helped improve patients’ quality of life and proved commercially successful. In early 2015, Xadago (Newron/Zambon), a third-in-class MAO-B inhibitor, became one of the first new drugs approved for PD in Europe in many years; the pipeline further includes several late-stage agents that have the potential to reach the market within the next three years. These new agents will enter an increasingly cost-sensitive environment, and marketers will need to provide clear evidence of clinical improvements and/or cost benefits over well-entrenched, often generically available standards-of-care to receive a favorable health technology assessment (HTA) and command premium pricing.